SYDNEY, AUSTRALIA – 04 March 2019 - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced its participation in Oppenheimer’s 29th Annual Healthcare Conference.
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.
Conference: Oppenheimer’s 29th Annual Healthcare Conference
Dates: 19 March 2019, from 9:10 AM to 9:40 AM Eastern Standard Time
Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, USA
Presenter: Marc Voigt, CEO of Immutep
The presentation is expected to be live webcasted. A link to the webcast will be made available on the Company’s website.
For further information please download PDF attached:
Download this document